α-Glucosidase Inhibition by Miglitol in NIDDM Patients

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Diabetes Care

• Publication date

  1992-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diacare.15.4.478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of 8-Wk α-Glucosidase Inhibition on Metabolic Control, C-Peptide Secretion, Hepatic Glucose Output, and Peripheral Insulin Sensitivity in Poorly Controlled Type II Diabetic Patients

  1989cited by this paper
• Metabolic and nutritional effects of long-term use of guar gum in the treatment of noninsulin-dependent diabetes of poor metabolic control.

  1989cited by this paper
• Predominant Role of Gluconeogenesis in Increased Hepatic Glucose Production in NIDDM

  1989cited by this paper
• The insulin and glucose responses to meals of glucose plus various proteins in type II diabetic subjects.

  1988cited by this paper
• Quantitative Importance of Dietary Constituents Other Than Glucose as Insulin Secretagogues in Type II Diabetes

  1988cited by this paper
• Effects of BAYm 1099, New α-Glucosidase Inhibitor, on Acute Metabolic Responses and Metabolic Control in NIDDM Over 1 Mo

  1988cited by this paper
• 1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a.

  1988cited by this paper
• The influence of guar-gum bread on the regulation of diabetes mellitus type II in elderly patients

  1987cited by this paper
• Pharmacological Modification of Digestion and Absorption

  1987cited by this paper
• Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.

  1986cited by this paper
• Effect of Acarbose on the 24-Hour Blood Glucose Profile and Pattern of Carbohydrate Absorption

  1982cited by this paper
• Fructose potentiation of insulin secretion.

  1972cited by this paper

• Structure-guided discovery of natural α-glucosidase inhibitors from food sources for blood sugar regulation

  2025cites this paper
• Randomized single oral dose phase 1 study of safety, tolerability, and pharmacokinetics of Iminosugar UV-4 Hydrochloride (UV-4B) in healthy subjects

  2022cites this paper
• Interaction of antidiabetic α‐glucosidase inhibitors and gut bacteria α‐glucosidase

  2018cites this paper
• Selected Phyto and Marine Bioactive Compounds: Alternatives for the Treatment of Type 2 Diabetes

  2018cites this paper
• A COMPARATIVE STUDY OF MIGLITOL AND ACARBOSE ADD ON THERAPY INTENDED FOR BETTER GLYCAEMIC CONTROL IN TYPE 2 DIABETES MELLITUS

  2016cites this paper
• Glucosyl epi‐cyclophellitol allows mechanism‐based inactivation and structural analysis of human pancreatic α‐amylase

  2016cites this paper
• Review: Miglitol has potential as a therapeutic drug against obesity

  2015cites this paper
• Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

  2015cites this paper
• Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients

  2014cites this paper
• Drug Therapy of Postprandial Hyperglycaemia

  2012cites this paper
• Newer insights into the drug delivery approaches of α-glucosidase inhibitors

  2012cites this paper
• Synthesis of 1-Deoxynojirimycin Derivatives from L-Sorbose via Wittig Reactions

  2011cites this paper
• Selective protecting group manipulations on the 1-deoxynojirimycin scaffold

  2007cites this paper
• Peptidomimetics, Glycomimetics and Scaffolds from Carbohydrate Building Blocks

  2007cites this paper
• Miglitol: Assessment of its Role in the Treatment of Patients with Diabetes Mellitus

  2000cites this paper
• The effects of miglitol and metformin on vitamin status in type 2 diabetes

  2000cites this paper
• Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

  2000influential citation
• Miglitol, a new alpha-glucosidase inhibitor.

  1999cites this paper
• Nuevos fármacos en el tratamiento de la diabetes mellitus tipo 2

  1999cites this paper
• Pharmacological management of diabetes: recent progress and future perspective in daily drug treatment.

  1999cites this paper
• Effect of miglitol administration to non-insulin-dependent diabetic rats.

  1998cites this paper
• The Efficacy and Safety of Miglitol Therapy Compared With Glibenclamide in Patients With NIDDM Inadequately Controlled by Diet Alone

  1997cites this paper
• Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s

  1997cites this paper
• Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.

  1996cites this paper
• Does Suppression of Postprandial Blood Glucose Excursions by the α-Glucosidase Inhibitor Miglitol Improve Insulin Sensitivity in Diet-Treated Type II Diabetic Patients?

  1996cites this paper
• New orally administered antihyperglycemic agents for the management of patients with type ii diabetes and the syndrome of insulin resistance.

  1996cites this paper
• In vitro study of the effect of miglitol on carbohydrate digestion and intestinal metabolism in normal and non-insulin-dependent diabetic rats.

  1996cites this paper
• New treatments for patients with type 2 diabetes mellitus.

  1996cites this paper
• Clinical Evaluation of Glucosidase Inhibitors

  1996cites this paper
• Drugs on the Horizon for Treatment of Type 2 Diabetes

  1995cites this paper
• Deoxynojirimycin: synthesis and biological activity.

  1994cites this paper
• An evaluation of the potential side‐effects of α‐glucosidase inhibitors used for the management of diabetes mellitus

  1994cites this paper
• Introduction

  1994cites this paper
• The roles of α‐glucosidase inhibitors in diabetes

  1994cites this paper